Published in Virol J on January 11, 2011
Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One (2014) 1.06
Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Load. J Clin Microbiol (2015) 1.05
Analytical characteristics and comparative evaluation of Aptima HIV-1 Quant Dx assay with Ampliprep/COBAS TaqMan HIV-1 test v2.0. Virol J (2016) 0.75
Statistical methods for assessing agreement between two methods of clinical measurement. Lancet (1986) 211.50
Real time quantitative PCR. Genome Res (1996) 35.79
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Measuring agreement in method comparison studies. Stat Methods Med Res (1999) 31.11
Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol (2000) 29.28
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Real-time PCR for mRNA quantitation. Biotechniques (2005) 7.80
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol (1994) 6.76
HIV-1 nomenclature proposal. Science (2000) 6.61
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res (1997) 4.40
Simultaneous amplification and detection of specific DNA sequences. Biotechnology (N Y) (1992) 4.28
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods (1991) 3.28
Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1998) 2.94
Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr (2007) 2.89
An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1996) 2.49
Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol (2007) 2.40
Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin. J Infect Dis (2007) 2.21
Genetic diversity of HIV-1: the moving target. AIDS (2000) 2.08
Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. J Clin Microbiol (2001) 1.97
Comparison of the Roche COBAS Amplicor Monitor, Roche COBAS Ampliprep/COBAS Taqman and Abbott RealTime Test assays for quantification of hepatitis C virus and HIV RNA. Clin Chem Lab Med (2007) 1.90
Human immunodeficiency virus type 1 quasispecies in vivo and ex vivo. Curr Top Microbiol Immunol (1992) 1.77
Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol (2005) 1.75
TaqMan 5'-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening. J Clin Microbiol (2001) 1.57
Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine. Clin Chem Lab Med (2007) 1.47
A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods (2007) 1.47
Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. J Virol Methods (2009) 1.45
Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol (1997) 1.43
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from Brazil. J Virol Methods (2006) 1.33
Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods (2006) 1.31
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J Virol Methods (2006) 1.30
Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. J Clin Microbiol (2009) 1.30
Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol (2007) 1.28
Impaired quantification of plasma HIV-1 RNA with a commercialized real-time PCR assay in a couple of HIV-1-infected individuals. J Clin Virol (2007) 1.27
Comparison of the Abbott realtime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. J Clin Microbiol (2009) 1.18
A new ultrasensitive assay for quantitation of HIV-1 RNA in plasma. J Virol Methods (2001) 1.10
Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay. J Clin Microbiol (1998) 0.99
Comparison of the LCx human immunodeficiency virus (HIV) RNA quantitative, RealTime HIV, and COBAS AmpliPrep-COBAS TaqMan assays for quantitation of HIV type 1 RNA in plasma. J Clin Microbiol (2006) 0.98
Comparison of the Abbott Realtime HIV-1 and HCV viral load assays with commercial competitor assays. Expert Rev Mol Diagn (2008) 0.91
HIV update. Diagnostic tests and markers of disease progression and response to therapy. Am J Clin Pathol (2002) 0.90
Plasma viral load testing in the management of HIV infection. Am Fam Physician (2001) 0.85
Comparison of three current viral load assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J Virol Methods (2004) 0.81
Comparison of TaqMan real-time PCR and p24 Elisa for quantification of in vitro HIV-1 replication. J Virol Methods (2003) 0.80
Updated antiretroviral treatment guidelines from DHHS and EACS. AIDS Clin Care (2008) 0.77
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin. J Infect Dis (2007) 2.21
Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother (2014) 2.18
Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis (2009) 2.13
Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. PLoS One (2013) 2.06
The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med (2009) 2.06
HBV viremia in newborns of HBsAg(+) predominantly Caucasian HBeAg(-) mothers. J Clin Virol (2010) 2.04
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS (2007) 2.00
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology (2012) 1.89
Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol (2006) 1.80
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73
Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS (2007) 1.72
Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther (2004) 1.72
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2002) 1.49
European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev (2011) 1.38
Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS (2004) 1.38
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr (2006) 1.27
Role of combination antiviral therapy in pandemic influenza and stockpiling implications. BMJ (2007) 1.22
Assessing the impact of biomedical research in academic institutions of disparate sizes. BMC Med Res Methodol (2009) 1.21
Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology (2013) 1.19
Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis (2003) 1.18
Socially-integrated transdisciplinary HIV prevention. AIDS Behav (2014) 1.18
HIV‑1 molecular epidemiology in the Balkans: a melting pot for high genetic diversity. AIDS Rev (2012) 1.16
Characterization of a novel vpu-harboring simian immunodeficiency virus from a Dent's Mona monkey (Cercopithecus mona denti). J Virol (2005) 1.13
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med (2010) 1.12
In vivo characteristics of human immunodeficiency virus type 1 intersubtype recombination: determination of hot spots and correlation with sequence similarity. J Gen Virol (2003) 1.09
Biological Warfare Plan in the 17th Century—the Siege of Candia, 1648–1669. Emerg Infect Dis (2015) 1.09
Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clin Infect Dis (2012) 1.09
The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis (2007) 1.07
Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PLoS Comput Biol (2013) 1.07
The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea. Pediatr Infect Dis J (2011) 1.07
Phylogenetic reconstruction of a known HIV-1 CRF04_cpx transmission network using maximum likelihood and Bayesian methods. J Mol Evol (2004) 1.03
Homelessness and Other Risk Factors for HIV Infection in the Current Outbreak Among Injection Drug Users in Athens, Greece. Am J Public Health (2015) 1.01
Limited cross-border infections in patients newly diagnosed with HIV in Europe. Retrovirology (2013) 1.01
Molecular characterization of occult hepatitis B cases in Greek blood donors. J Med Virol (2009) 0.97
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis (2014) 0.96
Financial crisis, austerity, and health in Europe. Lancet (2013) 0.95
Big Events in Greece and HIV Infection Among People Who Inject Drugs. Subst Use Misuse (2015) 0.94
The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis (2006) 0.93
Association of clinical progression in classic Kaposi's sarcoma with reduction of peripheral B lymphocytes and partial increase in serum immune activation markers. Arch Dermatol (2005) 0.91
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology (2012) 0.91
Risk associations of melanoma in a Southern European population: results of a case/control study. Cancer Causes Control (2008) 0.90
Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol (2009) 0.89
Prevalent genotypes of Toxoplasma gondii in pregnant women and patients from Crete and Cyprus. Am J Trop Med Hyg (2008) 0.89
Prevalence of different HPV types and estimation of prognostic risk factors based on the linear array HPV genotyping test. J Med Virol (2009) 0.89
HIV transmission patterns among The Netherlands, Suriname, and The Netherlands Antilles: a molecular epidemiological study. AIDS Res Hum Retroviruses (2010) 0.89
Transmission dynamics of carbapenemase-producing Klebsiella pneumoniae and anticipated impact of infection control strategies in a surgical unit. PLoS One (2012) 0.89
Subgenotype A1 of HBV--tracing human migrations in and out of Africa. Antivir Ther (2013) 0.89
Racial and ethnic disparities and implications for the prevention of HIV among persons who inject drugs. Curr Opin HIV AIDS (2012) 0.89
Development of a new ultra sensitive real-time PCR assay (ultra sensitive RTQ-PCR) for the quantification of HBV-DNA. Virol J (2010) 0.88
Epidemiologic risk factors of basal cell carcinoma development and age at onset in a Southern European population from Greece. Exp Dermatol (2011) 0.88
Human herpesvirus 8 (HHV-8) infection in healthy urban employees from Greece: seroprevalence and associated factors. J Med Virol (2007) 0.87
A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative. Hepatology (2005) 0.86
Recent HIV-1 Outbreak Among Intravenous Drug Users in Romania: Evidence for Cocirculation of CRF14_BG and Subtype F1 Strains. AIDS Res Hum Retroviruses (2014) 0.86
Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials. Stat Med (2008) 0.85
Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis (2005) 0.85
Impact of HIV type 1 DNA levels on spontaneous disease progression: a meta-analysis. AIDS Res Hum Retroviruses (2011) 0.84
Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine. J Clin Microbiol (2013) 0.83
HBV virological assessment. J Hepatol (2005) 0.83
Human herpesvirus 8 infection in hemodialysis patients. Am J Kidney Dis (2006) 0.83